FDA Delays Impacting Inflammatory Skin Disease Community

Video

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.

Related Videos
Related Content

Risankizumab Efficacious in Patients With Concomitant Psoriasis and HIV, Study Reports

October 2nd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023

Risankizumab Efficacious in Patients With Concomitant Psoriasis and HIV, Study Reports

October 2nd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023

Risankizumab Efficacious in Patients With Concomitant Psoriasis and HIV, Study Reports

October 2nd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023
© 2023 MJH Life Sciences

All rights reserved.